Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 0.65 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.62 |
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 0.50 |
| ▸ | TTR known ✓ | P02766 | 2/20 | 0.48 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33714 | 0.97 | — | — | |
| SCHEMBL28492119 | 0.85 | ESR2 (0.55) | ESR2CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL11490972 | 0.80 | CA1 (0.95) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL28124722 | 0.79 | ESR2 (1.00) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL534830 | 0.77 | — | — | |
| SCHEMBL31272965 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL10954400 | 0.76 | CA14 (0.56) | ESR2CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL4374970 | 0.74 | TSHR (0.94) | ESR2CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL10882631 | 0.74 | CYP3A4 (0.71) | ESR2CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL864592 | 0.74 | CYP3A4 (1.00) | ESR2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865887-A | Preparation method of lenvatinib mesylate intermediate | 山东鲁抗医药股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-115322149-A | Alvatinib mesylate impurity and preparation method thereof | 思科(深圳)药物研发有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-113024459-A | Alvatinib mesylate intermediate impurity and preparation method thereof | 重庆药友制药有限责任公司 | 2021-06-25 | — | — | CN | claimed |
| CN-111349045-A | Synthetic method of lenvatinib and novel intermediate | 江苏万邦生化医药集团有限责任公司 | 2020-06-30 | — | — | CN | claimed |
| US-20110224335-A1 | INK COMPOSITION AND METHOD OF FABRICATING LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | KIM SUNG-HEE | 2011-09-15 | — | — | US | claimed |
| US-7935552-B2 | Ink composition and method of fabricating liquid crystal display device using the same | LG DISPLAY CO., LTD. (KR) | 2011-05-03 | — | — | US | claimed |
| US-20100120181-A1 | INK COMPOSITION AND METHOD OF FABRICATING LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | LG DISPLAY CO., LTD. (KR) | 2010-05-13 | — | — | US | claimed |
| WO-2025120654-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TIVOZANIB HYDROCHLORIDE HYDRATE | NATCO PHARMA LIMITED (IN) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025072673-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS IRE 1 INHIBITORS | AL22.02.01, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-112654603-B | Preparation method of lenvatinib | 意迪那有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117865887-A | Preparation method of lenvatinib mesylate intermediate | 山东鲁抗医药股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117865887-A | Preparation method of lenvatinib mesylate intermediate | 山东鲁抗医药股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-111689897-B | Preparation method of high-purity lenvatinib mesylate crystal form C | 齐鲁制药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2001021596-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| US-6143743-A | TREATMENT OF NERVOUS SYSTEM DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0994877-A1 | IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Du Pont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001454-A1 | IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
| US-4065255-A | HUMAN HAIR | L'OREAL (FR) | 1977-12-27 | — | — | US | disclosed |
| US-3956342-A | HAIR DYE, HAIR SETTING LOTION | L'OREAL (FR) | 1976-05-11 | — | — | US | disclosed |
| US-3953508-A | Diphenylamines for dyeing keratinous fibers | L'OREAL (FR) | 1976-04-27 | — | — | US | disclosed |